Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP215229.RAzt5zDBxc0lAhYhjq2fGNJ4dSHXdM-gSVIHRnnJ52dCs130_provenance.
• NP240438.RAF7e16aY_9NhBncQY_zuwE-UfzquvLOJvanHDJzlgJi0130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP240438.RAF7e16aY_9NhBncQY_zuwE-UfzquvLOJvanHDJzlgJi0130_provenance.
• NP182098.RAtUj5ZO9x1VHPJQ2_v0pBecg51KCCE8IVE0_JJl2ZzhM130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP182098.RAtUj5ZO9x1VHPJQ2_v0pBecg51KCCE8IVE0_JJl2ZzhM130_provenance.
• assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP597603.RAY7UKyRL80W8EAuzIkUWte8Zp40dE10BcSsXve_Mv-SE130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP597603.RAY7UKyRL80W8EAuzIkUWte8Zp40dE10BcSsXve_Mv-SE130_provenance.
• NP946602.RAZH2p_gsThBJAPWIAWiWSeEghJswn4LSKz1KKOSsww5Y130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946602.RAZH2p_gsThBJAPWIAWiWSeEghJswn4LSKz1KKOSsww5Y130_provenance.
• assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP925921.RAcy64n86uCdXjemb7QLY4fMoSHrHOkzcVajczSIa7qR8130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925921.RAcy64n86uCdXjemb7QLY4fMoSHrHOkzcVajczSIa7qR8130_provenance.
• assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP946591.RAsyIdPLbWUyIXtvegS7hlJuUg_0cOx0TyPN7gt83rKdE130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946591.RAsyIdPLbWUyIXtvegS7hlJuUg_0cOx0TyPN7gt83rKdE130_provenance.
• NP925922.RAuwgdxhbW9INu9xD1swVtAkBsvfE05i4KaXC2TUQ05OI130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925922.RAuwgdxhbW9INu9xD1swVtAkBsvfE05i4KaXC2TUQ05OI130_provenance.
• NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_provenance.
• NP925925.RAg_oIDsYe6YUNsou5YqJRmF51sPZUdhFYIaypVfSMntk130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925925.RAg_oIDsYe6YUNsou5YqJRmF51sPZUdhFYIaypVfSMntk130_provenance.
• NP407988.RAGxloMFAU2MaD1Xye1DT9YIaK6hMxHB5OQg0uanxbY-8130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP407988.RAGxloMFAU2MaD1Xye1DT9YIaK6hMxHB5OQg0uanxbY-8130_provenance.
• NP925920.RA1zLteJXt39xFJJ0wLlS5lfKvdfyzFTrAsa7EJqw95mA130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925920.RA1zLteJXt39xFJJ0wLlS5lfKvdfyzFTrAsa7EJqw95mA130_provenance.
• NP925924.RA-wVNDBwL7yxdXWYkeOCda21FVn6jZWJrJqHzqCXy_VM130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925924.RA-wVNDBwL7yxdXWYkeOCda21FVn6jZWJrJqHzqCXy_VM130_provenance.